Press Releases

Jul 11, 2023

Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants

Jul 06, 2023

Vaxcyte Mourns the Sudden Passing of Board Member and Biopharmaceutical Industry Leader Michael Kamarck, Ph.D.

Jun 01, 2023

Vaxcyte to Present at the Jefferies Healthcare Conference

May 08, 2023

Vaxcyte Reports First Quarter 2023 Financial Results and Provides Business Update

May 03, 2023

Vaxcyte to Present at the BofA Securities 2023 Health Care Conference

Apr 21, 2023

Vaxcyte Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Apr 19, 2023

Vaxcyte Announces Pricing of $500 Million Public Offering

Apr 17, 2023

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

Apr 17, 2023

Vaxcyte Reports Positive Data from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate, VAX-24, in Adults Aged 65 and Older and Full Six-Month Safety Data from Adult Phase 1/2 and Phase 2 Studies

Apr 16, 2023

Vaxcyte to Host Webcast and Conference Call to Discuss Results from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate in Adults Aged 65 and Older and Full Six-Month Safety Data from Both Adult Phase 2 Studies

Displaying 11 - 20 of 26